Jip M. van Elst

Jip M. van Elst

Auto-generated profile, based on publicly available information

Jip M. van Elst

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
JEJip M. van Elst
Jip M. van Elst
NINikki IJzerman
Nikki IJzerman
RMRon Mathijssen
Ron Mathijssen
NSNeeltje Steeghs
Neeltje Steeghs
ARAnna K.L. Reyners
Anna K.L. Reyners
JHJacco de Haan
Jacco de Haan

3 November 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAdriana Tami
Adriana Tami
BGBernardina T. F. van der Gun
Bernardina T. F. van der Gun
KWKarin I. Wold
Karin I. Wold
MVMaría F. Vincenti-González
María F. Vincenti-González
AVAlida C. M. Veloo
Alida C. M. Veloo
AFAlex W. Friedrich
Alex W. Friedrich
Background: Guidelines on COVID-19 management are developed as we learn from this pandemic. However, most research has been done on hospitalised patients and the impact of the disease on non-hospitalised and their role in transmission are not yet well understood. The COVID HOME study conducts research among COVID-19 patients and their family members who were not hospitalised during acute disease, to guide patient care and inform public health guidelines for infection prevention and control in the community and household. Methods: An ongoing prospective longitudinal observational study of COVID-19 outpatients was established in March 2020 at the beginning of the COVID-19 pandemic in the Netherlands. Laboratory confirmed SARS-CoV-2 infected individuals of all ages that did not merit hospitalisation, and their household (HH) members, were enrolled after written informed consent. Enrolled participants were visited at home within 48 hours after initial diagnosis, and then weekly on days 7, 14 and 21 to obtain clinical data, a blood sample for biochemical parameters/cytokines and serological determination; and a nasopharyngeal/throat swab plus urine, stool and sperm or vaginal secretion (if consenting) to test for SARS-CoV-2 by RT-PCR (viral shedding) and for viral culturing. Weekly nasopharyngeal/throat swabs and stool samples, plus a blood sample on days 0 and 21 were also taken from HH members to determine whether and when they became infected. All participants were invited to continue follow-up at 3-, 6-, 12- and 18-months post-infection to assess long-term sequelae and immunological status.

12 November 2022 in Chemosensory Perception
Verified
Journal Article
Open access
PDF file
JEJip M. van Elst
Jip M. van Elst
SBSanne Boesveldt
Sanne Boesveldt
Arjan VissinkArjan Vissink
Arjan Vissink
HJHarriet Jager-Wittenaar
Harriet Jager-Wittenaar
ARAnna K.L. Reyners
Anna K.L. Reyners
JHJacco de Haan
Jacco de Haan
Introduction: The characteristics and impact of mouthfeel, temperature, smell, and taste alterations in patients with COVID-19 at a long term are yet not well known. In this study, these characteristics and their impact on daily life and quality of life (QoL) were assessed, six to ten months after infection, in patients with COVID-19 searching for peer support on Facebook. Methods: Between December 2020 and January 2021, members of two COVID-19 Facebook groups were invited to complete a questionnaire. Participants were asked to report their perception of mouthfeel, temperature, smell, and taste alterations and their impact. Results: The questionnaire was completed by 157/216 respondents (73%), with 92% being women. Alterations in mouthfeel, temperature, smell, and taste were reported by respectively 66, 40, 148, and 133 participants. The most frequently reported mouthfeel alterations were “a different feeling” and “dry mouth” in 38 and 30 participants, respectively. Preferences for food temperature were equally changed to “freezing”, “cool”, “room temperature”, “a bit warmer”, and “warmer”. An impact on daily life and QoL was reported by most patients with alterations in mouthfeel (91% and 79%), temperature (78% and 60%), smell (98% and 93%), and taste (93% and 88%), respectively. Conclusions: Patients with COVID-19 searching for peer support on Facebook experienced, next to smell and taste alterations, mouthfeel and temperature disturbances, six to ten months after infection. These alterations have an impact on daily life and QoL. Implications: Health professionals should, next to smell and taste alterations, be aware of mouthfeel and temperature alterations in patients with COVID-19.

21 May 2026 in Supportive Care in Cancer
Verified
Journal Article
Open access
JEJip M. van Elst
Jip M. van Elst
CBCorine M Buffinga
Corine M Buffinga
Henk BrandHenk Brand
Henk Brand
LHLucie B. M. Hijmering-Kappelle
Lucie B. M. Hijmering-Kappelle
HJHarriet Jager-Wittenaar
Harriet Jager-Wittenaar
JHJacco de Haan
Jacco de Haan
Purpose: To determine the prevalence and characteristics of persistent dysfunction of taste and smell, and salivary parameters in patients after completion of ICI therapy. Methods: In this cross-sectional study, dysfunction in patients treated for cancer with ICIs was compared with dysfunction in caregivers. Subjective taste and smell dysfunction and their impact on life were evaluated using validated questionnaires. Objective taste and smell were assessed with taste strips and Sniffin’ Sticks, and flow rate and biochemical composition of saliva were measured. Results: A total of 50 patients and 51 caregivers were included. General characteristics of patients did not differ significantly from those of caregivers. Patients had received a median of 14 ICI cycles. The median time since the last ICI cycle was 3.7 years. Six patients (12%) reported mild subjective taste alterations and two (4%) moderate taste alterations, while two caregivers (4%) reported mild taste alterations. Patients scored lower on the appetite subscale and higher on sodium concentration compared to caregivers (respectively, p = 0.017 and p = 0.027). Objective taste and smell function, (un)stimulated saliva flow rates, and xerostomia did not significantly differ between both groups. Conclusions: These findings suggest that most patients do not experience persistent taste and smell dysfunction, and salivary changes after ICI treatment. However, a subgroup reports symptoms. As subjective experiences may not correspond with objective findings, clinicians should actively inquire about perceived sensory dysfunction as these can impact QoL. Trial registration number: NCT06495008 / 2024–01-02.

18 May 2026 in Journal of Human Nutrition and Dietetics
Verified
Journal Article
Open access
PDF file
JEJip M. van Elst
Jip M. van Elst
KBKris Beukers
Kris Beukers
SBSandra Beijer
Sandra Beijer
MJMaryska Janssen‐Heijnen
Maryska Janssen‐Heijnen
ARAnna K.L. Reyners
Anna K.L. Reyners
JHJacco de Haan
Jacco de Haan
Background and Aims: Enjoying food is related to the taste, smell and texture of food, ambience during meals, presentation of the meals, and freedom to choose meals. A decrease in food enjoyment can lead to decreased food intake, undesired weight loss, and reduced quality of life. Cancer and cancer treatment can induce symptoms that affect food enjoyment. To optimise food enjoyment and intake, insight in the experiences and preferences of hospitalised patients with cancer is essential. This qualitative study aimed to explore the perspectives of patients with cancer on the experience of food and drinks, ambience during meals, timing of the meals, and the freedom to choose one's own meals, during hospital admission. Methods: In hospitalised patients with cancer treated with systemic therapy, 12 semi‐structured interviews were performed. Nutritional status was subjectively assessed, and taste and smell objectively to characterise the study population. Thematic analysis was used to identify key themes. Results: Three selective codes emerged: (1) the quality of hospital food and drinks, (2) the presentation of hospital food and drinks, and (3) meeting patients' preferences. Patients described hospital food, and in particular main meals, as bland, overcooked, and repetitive. Autonomy in meal choices and flexibility in portion sizes were appreciated but inconsistently facilitated. Ambiance was moderately important, with suggestions for communal dining areas. Presentation issues, including plastic odours and inconsistent meal temperatures, were mentioned. Patients valued personalised options such as additional seasonings or sauces. Conclusions: The eating experience of hospitalised cancer patients is shaped by various factors including quality of food, its presentation, and the ability to cater to individual preferences. By addressing these aspects and implementing a patient‐centred food service, care could be optimised in oncology wards.

22 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JEJip M. van Elst
Jip M. van Elst
ATAdriana Tami
Adriana Tami
MGMaría F. Vincenti González
María F. Vincenti González
KWKarin Wold
Karin Wold
LVLinda Acm Veloo
Linda Acm Veloo
JHJacco de Haan
Jacco de Haan
Objectives: This study aimed to longitudinally assess the prevalence and characteristics of olfactory, gustatory, and trigeminal changes, and the impact of these changes on daily life and quality of life (QoL) in non-hospitalized COVID-19 patients. Methods: Three weeks after confirmed COVID-19 diagnosis, non-hospitalized adult participants enrolled in the COVID HOME study consented to complete a questionnaire by phone on the presence, characteristics, and impact on daily life and QoL of olfactory, gustatory and/or trigeminal changes. Participants reporting taste and/or smell changes completed the same questionnaire at three months and, when still present, at six months. Results: The questionnaire was completed by 94/117 participants included in this study three weeks after COVID-19 diagnosis. The 43 participants with smell and/or taste changes completed the questionnaire at three months, and 19 at six months. Of the 94 participants, 56% were female and the median age was 43 [IQR 29-55] years. At three weeks post-infection, olfactory, gustatory, and trigeminal changes were reported by 40 (43%), 37 (39%), and 8 (9%) participants, respectively. During follow-up, olfactory, gustatory, and trigeminal changes were reported by 17 (40%), 14 (33%), and 3 (7%) at three months, and 12 (63%), 9 (47%), and 1 (5%) participants at six months, respectively. Most patients reported an impact of sensory changes on daily life and QoL, mostly describing it as a bit’ or ‘quite a bit’. However, impact did not differ between time points and most participants reported taking no action to cope with these changes. Participants with reported sensory alterations were most interested in professional help at six months. Conclusions: In non-hospitalized COVID-19 patients, the reported prevalence of olfactory, gustatory and trigeminal changes is higher three weeks after infection. Most patients report modest impact on daily life and QoL due to these sensory changes, and a subgroup reported a profound effect.